002287.SHE Tibet Cheezheng Tibetan Medicine Co Ltd
- Market cap
- CNY 10.7B
- P/E
- 16.7x
- P/B
- 2.14x
- ROE
- 10.8%
- Dividend yield
- 4.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002287.SHE undervalued?
Graham number002287.SHE trades 26.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tibet Cheezheng Tibetan Medicine Co Ltd fundamental analysis
No fundamental analysis for Tibet Cheezheng Tibetan Medicine Co Ltd yet.
Tibet Cheezheng Tibetan Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tibet Cheezheng Tibetan Medicine Co Ltd
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral Tibetan and traditional Chinese medicine products, external analgesics, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculoskeletal system, nervous sy…
Full company profileTibet Cheezheng Tibetan Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tibet Cheezheng Tibetan Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 968M | 1.05B | 1.21B | 1.40B | 1.49B | 1.77B | 2.04B | 2.05B | 2.34B | 2.42B | 1.79B |
| Gross Profit | 818M | 919M | 1.06B | 1.22B | 1.27B | 1.50B | 1.72B | 1.72B | 1.92B | 2.42B | 1.43B |
| Operating Income | 275M | 322M | 354M | 402M | 456M | 790M | 522M | 646M | 657M | 763M | 572M |
| EBITDA | 347M | 351M | 373M | 442M | 512M | 904M | 652M | 797M | 815M | 842M | 619M |
| Net Income | 290M | 301M | 319M | 364M | 404M | 716M | 473M | 581M | 582M | 646M | 543M |
| EPS | 0.55 | 0.57 | 0.60 | 0.69 | 0.76 | 1.35 | 0.89 | 1.10 | 1.10 | 1.19 | 0.95 |
| Balance Sheet | |||||||||||
| Total Assets | 2.08B | 2.30B | 2.31B | 2.98B | 4.46B | 5.57B | 5.89B | 6.30B | 6.79B | 6.92B | 6.61B |
| Total Liabilities | 324M | 403M | 268M | 722M | 1.82B | 2.35B | 2.50B | 2.53B | 2.68B | 1.92B | 1.56B |
| Shareholders' Equity | 1.73B | 1.88B | 2.03B | 2.25B | 2.62B | 3.17B | 3.34B | 3.72B | 4.06B | 4.95B | 5.00B |
| Cash & Short-term Investments | 458M | 386M | 396M | 1.38B | 1.83B | 1.85B | 1.98B | 2.37B | 3.00B | 376M | 123M |
| Total Debt | 116M | 220M | - | 300M | 1.21B | 1.45B | 1.70B | 1.52B | 1.61B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 389M | 230M | 499M | 406M | 239M | 1.03B | 286M | 693M | 457M | 730M | - |
| Capital Expenditure | 180M | 66.1M | 129M | 52.3M | 339M | 126M | 272M | 235M | 255M | 153M | 135M |
| Free Cash Flow | 209M | 164M | 370M | 354M | -100M | 909M | 13.3M | 459M | 201M | 577M | 139M |
| Ratios | |||||||||||
| ROE | 16.7% | 16.0% | 15.7% | 16.2% | 15.4% | 22.6% | 14.2% | 15.6% | 14.3% | 13.1% | 10.8% |
| ROA | 14.0% | 13.1% | 13.8% | 12.2% | 9.1% | 12.9% | 8.0% | 9.2% | 8.6% | 9.3% | 8.2% |
| Net Profit Margin | 29.9% | 28.6% | 26.3% | 26.0% | 27.2% | 40.4% | 23.1% | 28.4% | 24.9% | 26.7% | 30.4% |
| Debt to Equity | 0.07x | 0.12x | - | 0.13x | 0.46x | 0.46x | 0.51x | 0.41x | 0.40x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tibet Cheezheng Tibetan Medicine Co Ltd dividends
- Dividend yield
- 4.22%
- Forward dividend
- 0.64 CNY
- Payout ratio
- 70.1%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 453M | 0.83 | 70.1% |
| 2024 | CNY 282M | 0.53 | 48.5% |
| 2023 | CNY 220M | 0.42 | 37.9% |
| 2022 | CNY 313M | 0.59 | 66.2% |
| 2021 | CNY 180M | 0.34 | 25.2% |
| 2020 | CNY 186M | 0.35 | 45.9% |
| 2019 | CNY 166M | 0.31 | 45.7% |
| 2018 | CNY 175M | 0.33 | 55.0% |
| 2017 | CNY 162M | 0.31 | 53.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.298334:1 on Jul 11, 2019.
Who owns Tibet Cheezheng Tibetan Medicine Co Ltd
- Insiders 82.33%
- Institutions 0.47%
- Public & others 17.20%
- Shares outstanding 572M
- Free float 103M
Tibet Cheezheng Tibetan Medicine Co Ltd company profile
- Company name
- Tibet Cheezheng Tibetan Medicine Co Ltd
- Ticker
- 002287.SHE
- ISIN
- CNE100000FM9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 28, 2009
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,203
- Fiscal year end
- December
- Address
- No. 2, Deji Road, Nyingchi, China, 860000
- Phone
- 86 10 8476 6012
- Website
- cheezheng.com.cn
About Tibet Cheezheng Tibetan Medicine Co Ltd
Tibet Cheezheng Tibetan Medicine Co., Ltd. engages in the research, development, production, and sale of Tibetan medicines in China and internationally. The company also provides plasters, topical and oral Tibetan and traditional Chinese medicine products, external analgesics, and ointments. Its products are used in areas of orthopedics, neurology, dermatology, granules, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, musculoskeletal system, nervous system, respiratory, digestive, urinary, and cerebrovascular sectors. The company was founded in 1995 and is headquartered in Nyingchi, China. Tibet Cheezheng Tibetan Medicine Co., Ltd. is a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
Tibet Cheezheng Tibetan Medicine Co Ltd management
10- Mr. Haijian XiaPresident & Director · born 1975
- Ms. Guilan LuChief Financial Officer · born 1972
- Mr. Weiwu ChenChief Scientific Officer · born 1972
- Ms. Jianqin XiaoExecutive Vice President · born 1969
- Mr. Jun LiSenior Vice President · born 1975
- Ms. Ping FengSenior VP & Secretary of the Board of Directors · born 1970
- Mr. Tenzin WanmaDirector of Cultural Heritage · born 1981
- Ms. Min ZhaoVice President · born 1972
- Mr. Tianzhe LiVice President · born 1975
- Ai Ping ZhangAccounting Supervisor